2-(2,4-difluorophenylamino)-7-(2-morpholin-4-yl-propoxy)-10,11-dihydro-dibenzo[a,d]-cyclohepten-5-one | 1221486-30-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 二苯并环庚烯
• 英文名称: 2-(2,4-difluorophenylamino)-7-(2-morpholin-4-yl-propoxy)-10,11-dihydro-dibenzo[a,d]-cyclohepten-5-one
• 英文别名: 2-(2,4-Difluorophenylamino)-7-(3-morpholin-4-yl-propoxy)-10,11-dihydrodibenzo[a,d]-cyclohepten-5-one；13-(2,4-difluoroanilino)-5-(3-morpholin-4-ylpropoxy)tricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-one
• CAS: 1221486-30-1
• 化学式: C₂₈H₂₈F₂N₂O₃
• 分子量: 478.539
• InChiKey: YWWABRLUOWPDEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  50.8
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-chloro-7-methoxy-10,11-dihydro-dibenzo[a,d]cyclohepten-5-one 在 氢溴酸 、 palladium diacetate 、 potassium carbonate 、 溶剂黄146 、 sodium t-butanolate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 水 、 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 、 叔丁醇 为溶剂， 反应 21.75h， 生成 2-(2,4-difluorophenylamino)-7-(2-morpholin-4-yl-propoxy)-10,11-dihydro-dibenzo[a,d]-cyclohepten-5-one
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of Novel Disubstituted Dibenzosuberones as Highly Potent and Selective Inhibitors of p38 Mitogen Activated Protein Kinase

  摘要：

  Synthesis, biological testing, structure-activity relationships (SARs), and selectivity of novel disubstituted dibenzosuberone derivatives as p38 MAP kinase inhibitors are described. Hydrophilic moieties were introduced at the 7-, 8-, and 9-position of the 2-phenylamino-dibenzosuberones, improving physicochemical properties as well as potency. Extremely potent inhibitors were obtained, with half-maximal inhibitory concentration (IC50) values in the low nM range in a whole blood assay measuring the inhibition of cytokine release. The high potency of the target compounds together with the outstanding selectivity of this novel class of compounds toward p38 mitogen activated protein (MAP) kinase compared to other kinases indicate them to be most applicable as tools in pharmacological research and eventually they may foster a new generation of anti-inflammatory drugs.

  DOI：

  10.1021/jm300327h

文献信息

• DIBENZOCYCLOHEPTATONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS
  申请人：Laufer Stefan

  公开号：US20120115862A1

  公开（公告）日：2012-05-10

  The present invention relates to compounds of the formula I wherein R1, R2, R3, R4, X and Y have the meanings given in the description. The compounds have an action which is immunomodulating and inhibits or regulates the release of IL-1β and/or TNF-α. They can therefore be used for treatment of diseases connected with a disturbance in the immune system.

  本发明涉及公式I中的化合物，其中R1、R2、R3、R4、X和Y的含义如描述中所述。这些化合物具有免疫调节作用，并抑制或调节IL-1β和/或TNF-α的释放。因此，它们可以用于治疗与免疫系统紊乱有关的疾病。
• Dibenzocycloheptatone derivatives and pharmaceutical agents containing said compounds
  申请人：Laufer Stefan

  公开号：US08633312B2

  公开（公告）日：2014-01-21

  The present invention relates to compounds of the formula I wherein R1, R2, R3, R4, X and Y have the meanings given in the description. The compounds have an action which is immunomodulating and inhibits or regulates the release of IL-1β and/or TNF-α. They can therefore be used for treatment of diseases connected with a disturbance in the immune system.

  本发明涉及式I的化合物，其中R1、R2、R3、R4、X和Y具有描述中所给的含义。这些化合物具有免疫调节作用，并抑制或调节IL-1β和/或TNF-α的释放。因此，它们可用于治疗与免疫系统紊乱有关的疾病。
• DIBENZOCYCLOHEPTANONDERIVATE UND PHARMAZEUTISCHE MITTEL, WELCHE DIESE VERBINDUNGEN ENTHALTEN
  申请人：c-a-i-r biosciences GmbH

  公开号：EP2349964B1

  公开（公告）日：2015-09-09
• US8633312B2
  申请人：——

  公开号：US8633312B2

  公开（公告）日：2014-01-21
• [DE] DIBENZOCYCLOHEPTANONDERIVATE UND PHARMAZEUTISCHE MITTEL, WELCHE DIESE VERBINDUNGEN ENTHALTEN<br/>[EN] DIBENZOCYCLOHEPTANONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS<br/>[FR] DÉRIVÉS DIBENZOCYCLOHEPTANONE ET AGENTS PHARMACEUTIQUES CONTENANT CES COMPOSÉS
  申请人：C A I R BIOSCIENCES GMBH

  公开号：WO2010040843A2

  公开（公告）日：2010-04-15

  Die vorliegende Erfindung betrifft Verbindungen der Formel (I) worin R1, R2, R3, R4, X und Y die in der Beschreibung angegebenen Bedeutungen besitzen. Die Verbindungen besitzen immunmodulierende und die Freisetzung von IL-1β und/oder TNF-α inhibierende bzw. regulierende Wirkung. Sie sind daher zur Behandlung von Erkrankungen brauchbar, die im Zusammenhang mit einer Störung des Immunsystems stehen.